CA2953732C - Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor - Google Patents

Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor Download PDF

Info

Publication number
CA2953732C
CA2953732C CA2953732A CA2953732A CA2953732C CA 2953732 C CA2953732 C CA 2953732C CA 2953732 A CA2953732 A CA 2953732A CA 2953732 A CA2953732 A CA 2953732A CA 2953732 C CA2953732 C CA 2953732C
Authority
CA
Canada
Prior art keywords
braf
seq
nras
mutation
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2953732A
Other languages
English (en)
French (fr)
Other versions
CA2953732A1 (en
Inventor
Mitchell Paul LEVESQUE
Reinhard DUMMER
Daniel Widmer
Marieke Ineke Geertje Raaijmakers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51210291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2953732(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Publication of CA2953732A1 publication Critical patent/CA2953732A1/en
Application granted granted Critical
Publication of CA2953732C publication Critical patent/CA2953732C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CA2953732A 2014-07-14 2015-07-13 Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor Active CA2953732C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14176944.8 2014-07-14
EP14176944 2014-07-14
PCT/EP2015/065986 WO2016008853A1 (en) 2014-07-14 2015-07-13 Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor

Publications (2)

Publication Number Publication Date
CA2953732A1 CA2953732A1 (en) 2016-01-21
CA2953732C true CA2953732C (en) 2023-09-26

Family

ID=51210291

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2953732A Active CA2953732C (en) 2014-07-14 2015-07-13 Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor

Country Status (7)

Country Link
US (1) US20190194757A1 (enExample)
EP (1) EP3169797B2 (enExample)
JP (1) JP7036594B2 (enExample)
CN (1) CN107148481A (enExample)
CA (1) CA2953732C (enExample)
ES (1) ES2751925T5 (enExample)
WO (1) WO2016008853A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX393780B (es) 2017-01-17 2025-03-24 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos
WO2018213302A1 (en) * 2017-05-16 2018-11-22 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical braf mutations
CN112795647B (zh) * 2019-11-14 2022-08-16 北京肿瘤医院(北京大学肿瘤医院) 一种肿瘤标志物及其应用
CN111020033A (zh) * 2019-12-24 2020-04-17 中山大学达安基因股份有限公司 多重检测braf基因突变的试剂盒及方法
EP4359781A4 (en) * 2021-06-23 2025-05-14 Royal Melbourne Institute of Technology CONDUCTOMETRIC SENSOR FOR DETECTING A NUCLEIC ACID AND ITS DETECTION METHOD

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120252015A1 (en) * 2011-02-18 2012-10-04 Bio-Rad Laboratories Methods and compositions for detecting genetic material
CN103911428B (zh) * 2009-03-27 2016-02-24 生命技术公司 用于检测等位基因变体的方法、组合物和试剂盒
US20130315934A1 (en) * 2010-10-28 2013-11-28 Yale University Methods and Compositions for Assessing and Treating Cancer
WO2012061683A2 (en) 2010-11-05 2012-05-10 Glaxosmithkline Llc Methods for treating cancer
WO2012068468A1 (en) * 2010-11-19 2012-05-24 Glaxosmithkline Llc Method of treatment with braf inhibitor
WO2012068562A2 (en) * 2010-11-19 2012-05-24 The Regents Of The University Of California Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
WO2014009318A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh 3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer
WO2014009319A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Indolinone derivatives anticancer compounds
WO2014052613A2 (en) 2012-09-26 2014-04-03 Insight Genetics, Inc. Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers

Also Published As

Publication number Publication date
WO2016008853A1 (en) 2016-01-21
CA2953732A1 (en) 2016-01-21
JP2017529094A (ja) 2017-10-05
EP3169797A1 (en) 2017-05-24
EP3169797B2 (en) 2025-02-19
ES2751925T5 (en) 2025-05-13
ES2751925T3 (es) 2020-04-02
US20190194757A1 (en) 2019-06-27
JP7036594B2 (ja) 2022-03-15
EP3169797B1 (en) 2019-08-21
CN107148481A (zh) 2017-09-08

Similar Documents

Publication Publication Date Title
Lignitto et al. Nrf2 activation promotes lung cancer metastasis by inhibiting the degradation of Bach1
Cherry et al. Alternative splicing and cancer: insights, opportunities, and challenges from an expanding view of the transcriptome
Gao et al. Biology and clinical implications of the 19q13 aggressive prostate cancer susceptibility locus
Carvalho et al. Lack of microRNA‐101 causes E‐cadherin functional deregulation through EZH2 up‐regulation in intestinal gastric cancer
Cai et al. ZFX mediates non-canonical oncogenic functions of the androgen receptor splice variant 7 in castrate-resistant prostate cancer
Okholm et al. Circular RNA expression is abundant and correlated to aggressiveness in early-stage bladder cancer
Ling et al. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer
Pflueger et al. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing
Bellido et al. Association between germline mutations in BRF1, a subunit of the RNA polymerase III transcription complex, and hereditary colorectal cancer
Cook et al. Aberrant expression and subcellular localization of ECT2 drives colorectal cancer progression and growth
Liu et al. Rare deleterious germline variants and risk of lung cancer
Barbieri et al. Molecular genetics of prostate cancer: emerging appreciation of genetic complexity
CA2953732C (en) Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor
WO2012040614A1 (en) Compositions and methods for detecting cancer metastasis
Lin et al. Genetic interactions reveal distinct biological and therapeutic implications in breast cancer
Shi et al. The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA
de Bony et al. Comprehensive identification of long noncoding RNAs in colorectal cancer
Galvan et al. Germline polymorphisms and survival of lung adenocarcinoma patients: a genome‐wide study in two European patient series
KR20180108820A (ko) 암 후생유전적 프로파일링
Tombolan et al. NELL1, whose high expression correlates with negative outcomes, has different methylation patterns in alveolar and embryonal rhabdomyosarcoma
Flynn et al. Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles
Yang et al. GATA2 co-opts TGFβ1/SMAD4 oncogenic signaling and inherited variants at 6q22 to modulate prostate cancer progression
Nawrocka et al. Profile of basal cell carcinoma mutations and copy number alterations-focus on gene-associated noncoding variants
Gara et al. GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma and APOBEC3B is directly transcriptionally regulated by GATA3
Bersani et al. Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170103

EEER Examination request

Effective date: 20170103

EEER Examination request

Effective date: 20170103

EEER Examination request

Effective date: 20170103

EEER Examination request

Effective date: 20170103

EEER Examination request

Effective date: 20170103

EEER Examination request

Effective date: 20170103